Reply To: Ocrelizumab – a breakthrough?

October 7, 2019 at 3:59 pm

Genentech isn’t presently sponsoring any Clinical Trials of Ocrevus for treatment of CIDP. This may be due to the rarity of CIDP in comparison to MS and they may not have additional research funds available at this time for the extra research.

However, another new drug Rozanolixizumab (given subcutaneously) is being researched for use in treating CIDP. It is already being used to successfully treat cases of Myasthenia Gravis.

Rozanolixizumab has some similarities to Ocrelizumab in that it targets CD20-positive B cells, but in addition reduces Serum IgG and IgG Autoantibodies. The Clinical trial (partly being conducted at USC-Keck in Los Angeles) is here: